Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

Standard

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. / Worm, Signe W; Bower, Mark; Reiss, Peter; Bonnet, Fabrice; Law, Matthew; Fätkenheuer, Gerd; d'Arminio Monforte, Antonella; Abrams, Donald I; Grulich, Andrew; Fontas, Eric; Kirk, Ole; Furrer, Hansjakob; De Wit, Stephane; Phillips, Andrew; Lundgren, Jens D; Sabin, Caroline A; D:A:D study Group.

in: BMC INFECT DIS, Jahrgang 13, 01.01.2013, S. 471.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Worm, SW, Bower, M, Reiss, P, Bonnet, F, Law, M, Fätkenheuer, G, d'Arminio Monforte, A, Abrams, DI, Grulich, A, Fontas, E, Kirk, O, Furrer, H, De Wit, S, Phillips, A, Lundgren, JD, Sabin, CA & D:A:D study Group 2013, 'Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study', BMC INFECT DIS, Jg. 13, S. 471. https://doi.org/10.1186/1471-2334-13-471

APA

Worm, S. W., Bower, M., Reiss, P., Bonnet, F., Law, M., Fätkenheuer, G., d'Arminio Monforte, A., Abrams, D. I., Grulich, A., Fontas, E., Kirk, O., Furrer, H., De Wit, S., Phillips, A., Lundgren, J. D., Sabin, C. A., & D:A:D study Group (2013). Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC INFECT DIS, 13, 471. https://doi.org/10.1186/1471-2334-13-471

Vancouver

Bibtex

@article{95aa2dba81944335b8ef5f53b29f7faa,
title = "Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study",
abstract = "BACKGROUND: Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these.METHODS: Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression.RESULTS: Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort.CONCLUSIONS: The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.",
author = "Worm, {Signe W} and Mark Bower and Peter Reiss and Fabrice Bonnet and Matthew Law and Gerd F{\"a}tkenheuer and {d'Arminio Monforte}, Antonella and Abrams, {Donald I} and Andrew Grulich and Eric Fontas and Ole Kirk and Hansjakob Furrer and {De Wit}, Stephane and Andrew Phillips and Lundgren, {Jens D} and Sabin, {Caroline A} and {D:A:D study Group} and {van Lunzen}, Jan",
year = "2013",
month = jan,
day = "1",
doi = "10.1186/1471-2334-13-471",
language = "English",
volume = "13",
pages = "471",
journal = "BMC INFECT DIS",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

AU - Worm, Signe W

AU - Bower, Mark

AU - Reiss, Peter

AU - Bonnet, Fabrice

AU - Law, Matthew

AU - Fätkenheuer, Gerd

AU - d'Arminio Monforte, Antonella

AU - Abrams, Donald I

AU - Grulich, Andrew

AU - Fontas, Eric

AU - Kirk, Ole

AU - Furrer, Hansjakob

AU - De Wit, Stephane

AU - Phillips, Andrew

AU - Lundgren, Jens D

AU - Sabin, Caroline A

AU - D:A:D study Group

AU - van Lunzen, Jan

PY - 2013/1/1

Y1 - 2013/1/1

N2 - BACKGROUND: Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these.METHODS: Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression.RESULTS: Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort.CONCLUSIONS: The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.

AB - BACKGROUND: Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these.METHODS: Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression.RESULTS: Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort.CONCLUSIONS: The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.

U2 - 10.1186/1471-2334-13-471

DO - 10.1186/1471-2334-13-471

M3 - SCORING: Journal article

C2 - 24106926

VL - 13

SP - 471

JO - BMC INFECT DIS

JF - BMC INFECT DIS

SN - 1471-2334

ER -